The Conversation (0)
ENDRA Life Sciences contracted with the Centre for Imaging Technology Commercialization to start studies with their Thermo Acoustic Enhanced Ultrasound device targeting non-alcoholic fatty liver disease.
ENDRA Life Sciences (NASDAQ:NDRA) contracted with the Centre for Imaging Technology Commercialization to start studies with their Thermo Acoustic Enhanced Ultrasound (TAEUS) device targeting non-alcoholic fatty liver disease.
As quoted in the press release:
Francois Michelon, ENDRA’s Chairman and CEO, commented, “The contract with CIMTEC is a key milestone in ENDRA’s roadmap for its TAEUS technology and is one of several planned commercial and academic collaborations that will advance ENDRA’s TAEUS technology in the area of liver disease. ENDRA’s operating model and culture are built on capital efficiency and execution speed. Working with a high-quality CRO like CIMTEC supports ENDRA’s plan to introduce a commercial liver product supported by human studies in 2018.”
Michael Thornton, ENDRA’s Chief Technology Officer, explained, “These human studies with CIMTEC will involve both conventional ultrasound and TAEUS imaging, along with relevant blood markers and magnetic resonance imaging (MRI). Our objective is to obtain important insight into clinical work flow and ENDRA’s TAEUS quantitative methodologies.”
Click here to read the full press release.
Source: www.accesswire.com
